A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus
A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Placebo
- drug : VPD-737
Phase: Phase 2
Ages Eligible For Study:
- Clinical diagnosis of chronic pruritus and unresponsive to current therapies